Effectiveness of intragastric balloon for obesity: A systematic review and meta-analysis based on randomized control trials

Moura, Diogo Turiani Hourneaux de; Oliveira, Joel Fernandez de; Moura, Eduardo Guimarães Hourneaux de; Bernardo, Wanderlei M.; Neto, Manuel Galvão; Campos, Josemberg Marins; Popov, Violeta; Thompson, Christopher D.

doi:10.1016/j.soard.2015.10.077

Cited by 87 publications

(41 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[10] Conversely, endoscopic intragastric balloon (IGB) insertion is a noninvasive method that produces weight reduction in up to 35% of patients according to randomized controlled trials. [1112] Liraglutide (Victoza ® , Novo Nordisk, Bagsvaerd, Denmark), a parenteral glucagon-like peptide type 1 (GLP-1) agonist used to treat DM-2 that has a weight reducing effect, was approved by the food and drug administration (FDA) in 2013 for the treatment of DM-2 and in 2014 for weight reduction (www.fda.gov). Liraglutide is considered an expensive medication with an average monthly cost of 500$ for those without medical insurance.…”

mentioning

confidence: 99%

Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?

Mosli

Elyas

2017

Saudi J Gastroenterol

View full text Add to dashboard Cite

mentioning

confidence: 99%

Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?

Mosli

Elyas

2017

Saudi J Gastroenterol

View full text Add to dashboard Cite

“…After 6 months the balloon should be removed. The method seems to be an easy and safe, however the effect on excess weight loss is limited-14-32% at 6 months (14,15). Intra-gastric balloon is recommended for temporary use for bariatric patients with high BMI as a bridge to surgery.…”

Section: Intragastric Balloon Therapy (Figure 2)mentioning

confidence: 99%

“…Complications of intragastric balloon include aspiration, migration into small intestine with possible bowel obstruction, or gastric perforation. The last complication has been observed especially after prolonged use of the device (15).…”

Section: Intragastric Balloon Therapy (Figure 2)mentioning

confidence: 99%

Innovative solutions in bariatric surgery

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Additionally, for some patients with class I and II obesity who do not meet the criteria for surgery and those with class III obesity who do not want to undergo surgery, EBMTs may represent a feasible option for the treatment of obesity and potentially other metabolic comorbidities. [1][2][3][4][5][6] Aspiration therapy (AT) is one of the available EBMTs that utilizes a device called the AspireAssist (Aspire Bariatrics, King of Prussia, PA, USA). The device was approved by the Food and Drug Administration in 2016 for long-term use in conjunction with lifestyle therapy (LT) for people with body mass index (BMI) of 35-55 kg/m 2 .…”

Section: Introductionmentioning

confidence: 99%

Effect of Aspiration Therapy on Obesity-Related Comorbidities: Systematic Review and Meta-Analysis

et al. 2020

View full text Add to dashboard Cite

Background/Aims: Aspiration therapy (AT) involves endoscopic placement of a gastrostomy tube with an external device that allows patients to drain 30% of ingested calories after meals. Its efficacy for inducing weight loss has been shown. This study aimed to assess the effect of AT on obesity-related comorbidities. Methods: A meta-analysis of studies that assessed AT outcomes was conducted through December 2018. Primary outcomes were changes in comorbidities at 1 year following AT. Secondary outcomes were the amount of weight loss at up to 4 years and pooled serious adverse events (SAEs). Results: Five studies with 590 patients were included. At 1 year, there were improvements in metabolic conditions: mean difference (MD) in systolic blood pressure: -7.8 (-10.7 --4.9) mm Hg; MD in diastolic blood pressure: -5.1 (-7.0 -3.2) mm Hg; MD in triglycerides: -15.8 (-24.0 --7.6) mg/dL; MD in high-density lipoprotein: 3.6 (0.7-6.6) mg/dL; MD in hemoglobin A1c (HbA1c): -1.3 (-1.8 --0.8) %; MD in aspartate transaminase: -2.7 (-4.1 --1.3) U/L; MD in alanine transaminase: -7.5 (-9.8 --5.2) U/L. At 1 (n=218), 2 (n=125), 3 (n=46), and 4 (n=27) years, the patients experienced 17.8%, 18.3%, 19.1%, and 18.6% total weight loss (TWL), corresponding to 46.3%, 46.2%, 48.0%, and 48.7% excess weight loss (EWL) (p<0.0001 for all). Subgroup analysis of 2 randomized controlled trials (n=225) showed that AT patients lost more weight than did controls by 11.6 (6.5-16.7) 3) %EWL and experienced greater improvement in HbA1c and alanine transaminase by 1.3 (0.8-1.8) % and 9.0 (3.9-14.0) U/L. The pooled SAE rate was 4.1%. Conclusions: Obesity-related comorbidities significantly improved at 1 year following AT. Additionally, a subgroup of patients who continued to use AT appeared to experience significant weight loss that persisted up to at least 4 years. Clin Endosc 2020 Feb 28. [Epub ahead of print]

show abstract

Effectiveness of intragastric balloon for obesity: A systematic review and meta-analysis based on randomized control trials

Cited by 87 publications

References 27 publications

Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?

Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?

Innovative solutions in bariatric surgery

Effect of Aspiration Therapy on Obesity-Related Comorbidities: Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About